Recombinant CDKN2A anticorps
-
- Antigène Voir toutes CDKN2A Anticorps
- CDKN2A (Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A))
- Type d'anticorp
- Recombinant Antibody
-
Reactivité
- Humain
-
Hôte
- Lapin
-
Clonalité
- Monoclonal
-
Conjugué
- Cet anticorp CDKN2A est non-conjugé
-
Application
- Western Blotting (WB), Immunohistochemistry (Formalin-fixed Sections) (IHC (f))
- Specificité
- P16INK4a is a tumor suppressor protein. It is a specific inhibitor of cdk4/cdk6, and a tumor suppressor involved in the pathogenesis of a variety of malignancies. Recent analyses of the p16INK4a gene revealed homozygous deletions, nonsense, missense, or frameshift mutations in several human cancers. Although the frequency of p16INK4a abnormalities is higher in tumor derived cell lines than in unselected primary tumors, significant subsets of clinical cases with aberrant p16INK4a gene have been reported among melanomas, gliomas, esophageal, pancreatic, lung, and urinary bladder carcinomas, and some types of leukemia. Expression of p16INK4a (p16 positive) is highly correlated with human papilloma virus (HPV) infection in head and neck squamous cell carcinomas (HNSCC). p16 status is an important prognostic indicator in HNSCC and the p16 positive/HPV16 negative group is likely a distinct subgroup lacking any HPV genotype.
- Réactivité croisée (Details)
- Human.
- Purification
- 200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G.
- Immunogène
- Purified recombinant prokaryotic full-length human p16INK4a protein
- Isotype
- IgG
- Top Product
- Discover our top product CDKN2A Anticorps primaire
-
-
- Indications d'application
-
Positive Control: Human cervical squamous cell carcinoma.
Known Application: Western Blot (1-2 μg/mL),Immunohistochemistry (Formalin-fixed) (1-2 μg/mL for 30 minutes at RT),(Staining of formalin-fixed tissues requires heating tissue sections in 10 mM Tris with 1 mM EDTA, pH 9.0, for 45 min at 95 °C followed by cooling at RT for 20 minutes),Optimal dilution for a specific application should be determined.
- Restrictions
- For Research Use only
-
- Concentration
- 200 μg/mL
- Buffer
- Prepared in 10 mM PBS with 0.05 % BSA and 0.05 % azide.
- Agent conservateur
- Sodium azide
- Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Stock
- 4 °C,-80 °C
- Stockage commentaire
- Antibody with azide - store at 2 to 8 °C. Antibody is stable for 24 months. Non-hazardous. Also available WITHOUT BSA & azide at 1.0mg/ml.
- Date de péremption
- 24 months
-
- Antigène
- CDKN2A (Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A))
- Autre désignation
- CDKN2A (CDKN2A Produits)
- Synonymes
-
anticorps Arf, anticorps p16, anticorps MTS1, anticorps INK4A, anticorps p19ARF, anticorps p16Cdkn2a, anticorps ARF, anticorps CDK4I, anticorps CDKN2, anticorps CMM2, anticorps INK4, anticorps MLM, anticorps MTS-1, anticorps P14, anticorps P14ARF, anticorps P16, anticorps P16-INK4A, anticorps P16INK4, anticorps P16INK4A, anticorps P19, anticorps P19ARF, anticorps TP16, anticorps ARF-INK4a, anticorps INK4a-ARF, anticorps Ink4a/Arf, anticorps Pctr1, anticorps p16(INK4a), anticorps p16INK4a, anticorps p19
, anticorps cyclin-dependent kinase inhibitor 2A, anticorps cyclin dependent kinase inhibitor 2A, anticorps Cdkn2a, anticorps LOC100731972, anticorps LOC100340625, anticorps CDKN2A - Sujet
-
CDK4 inhibitor p16 INK4, CDK4I, CDKN2A, Cell cycle negative regulator beta, CMM2, Cyclin dependent kinase 4 inhibitor A, Melanoma p16 inhibits CDK4, MLM, MTS1, Multiple tumor suppressor 1, p14, p16, p19, P19ARF, TP16,P16INK4a
Cellular localisation: Nucleus. Cytoplasm. - Poids moléculaire
- 14kDa
- ID gène
- 1029, 512599
- UniProt
- P42771
- Pathways
- Mitotic G1-G1/S Phases, Stem Cell Maintenance, Positive Regulation of Endopeptidase Activity, Autophagy, Positive Regulation of Response to DNA Damage Stimulus
-